Takuya Hinoda1, Yasutaka Fushimi1, Tomohisa Okada2, Yoshiki Arakawa3, Chunlei Liu4, Akira Yamamoto1, Tsutomu Okada1, Kazumichi Yoshida3, Susumu Miyamoto3, Kaori Togashi1. 1. Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Sakyoku, Kyoto, Japan. 2. Human Brain Research Center, Kyoto University Graduate School of Medicine, Sakyoku, Kyoto, Japan. 3. Department of Neurosurgery, Kyoto University Graduate School of Medicine. Sakyoku, Kyoto, Japan. 4. Brain Imaging and Analysis Center and Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.
Abstract
PURPOSE: Gadolinium deposition in dentate nucleus (DN) has been reported after serial administration of gadolinium-based contrast agents (GBCAs). Gadolinium complexes have paramagnetic properties; therefore, we evaluated susceptibility changes of gadolinium deposition in DN using quantitative susceptibility mapping (QSM) for patients after serial administration of GBCAs. MATERIALS AND METHODS: In all, 48 patients with brain tumors, who had had serial GBCA administrations (GBCA group), and 48 healthy volunteers without any history of GBCA administrations (non-GBCA group) were enrolled in this study. Susceptibility values in DN on QSM and DN-to-cerebellum signal intensity ratios on unenhanced T1 -weighted images (T1 ratios) on 3T were analyzed. The relationship between the number of times of GBCA administrations and susceptibility values or T1 ratios were evaluated in the GBCA group. RESULTS: Susceptibility values at DN in the GBCA group were 0.107 ± 0.029 ppm, and significantly higher than those of the non-GBCA group (0.079 ± 0.025 ppm) (P < 0.0001). T1 ratios in DN of the GBCA group were 1.059 ± 0.070, and also significantly higher than that of the non-GBCA group (0.993 ± 0.016) (P < 0.0001). Spearman rank correlation coefficients between susceptibility values and the number of times of linear GBCA administration showed a modest significant correlation (ρ = 0.45, P = 0.0015). There was good correlation between T1 ratios and the number of times of linear GBCA administration, as reported previously (ρ = 0.76, P < 0.0001). CONCLUSION: Susceptibility values on QSM in DN of the GBCA group, after serial administration of GBCAs, were significantly higher than those of the non-GBCA group. Evidence Level: 3 J. MAGN. RESON. IMAGING 2017;45:1352-1358.
PURPOSE:Gadolinium deposition in dentate nucleus (DN) has been reported after serial administration of gadolinium-based contrast agents (GBCAs). Gadolinium complexes have paramagnetic properties; therefore, we evaluated susceptibility changes of gadolinium deposition in DN using quantitative susceptibility mapping (QSM) for patients after serial administration of GBCAs. MATERIALS AND METHODS: In all, 48 patients with brain tumors, who had had serial GBCA administrations (GBCA group), and 48 healthy volunteers without any history of GBCA administrations (non-GBCA group) were enrolled in this study. Susceptibility values in DN on QSM and DN-to-cerebellum signal intensity ratios on unenhanced T1 -weighted images (T1 ratios) on 3T were analyzed. The relationship between the number of times of GBCA administrations and susceptibility values or T1 ratios were evaluated in the GBCA group. RESULTS: Susceptibility values at DN in the GBCA group were 0.107 ± 0.029 ppm, and significantly higher than those of the non-GBCA group (0.079 ± 0.025 ppm) (P < 0.0001). T1 ratios in DN of the GBCA group were 1.059 ± 0.070, and also significantly higher than that of the non-GBCA group (0.993 ± 0.016) (P < 0.0001). Spearman rank correlation coefficients between susceptibility values and the number of times of linear GBCA administration showed a modest significant correlation (ρ = 0.45, P = 0.0015). There was good correlation between T1 ratios and the number of times of linear GBCA administration, as reported previously (ρ = 0.76, P < 0.0001). CONCLUSION: Susceptibility values on QSM in DN of the GBCA group, after serial administration of GBCAs, were significantly higher than those of the non-GBCA group. Evidence Level: 3 J. MAGN. RESON. IMAGING 2017;45:1352-1358.
Authors: Kevin M Koch; Matthew F Koff; Thomas W Bauer; Parina H Shah; Andrew S Nencka; S Sivaram Kaushik; Hollis G Potter Journal: Magn Reson Med Date: 2017-06-22 Impact factor: 4.668
Authors: Kofi Deh; Keigo Kawaji; Marjolein Bulk; Louise Van Der Weerd; Emelie Lind; Pascal Spincemaille; Kelly McCabe Gillen; Johan Van Auderkerke; Yi Wang; Thanh D Nguyen Journal: Magn Reson Med Date: 2018-10-04 Impact factor: 4.668
Authors: Jonathan R Young; Joe Qiao; Iren Orosz; Noriko Salamon; Mark A Franke; Hyun J Kim; Whitney B Pope Journal: Eur Radiol Date: 2018-05-09 Impact factor: 5.315
Authors: Robert Zivadinov; Niels Bergsland; Jesper Hagemeier; Deepa P Ramasamy; Michael G Dwyer; Ferdinand Schweser; Channa Kolb; Bianca Weinstock-Guttman; David Hojnacki Journal: Neurology Date: 2019-07-08 Impact factor: 11.800